

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Canceled)
2. (Previously presented) A denatured collagen type-IV selective peptide antagonist comprising a core amino acid sequence SEQ ID NO. 1: L-K-Q-N-G-G-N-F-S-L.
- 3-5. (Canceled)
6. (Original) The antagonist of claim 2 wherein the binding affinity of the denatured collagen type-IV selective antagonist to denatured type-IV collagen is substantially greater than the binding affinity of said antagonist to native collagen type-IV.
7. (Original) The antagonist of claim 2 wherein the binding affinity of the selective denatured collagen type-IV antagonist to denatured type-IV collagen is 100-fold greater than the binding affinity of said antagonist to native collagen.
8. (Original) The antagonist of claim 2 wherein the selective denatured collagen type-IV antagonist inhibits cellular interaction with denatured collagen type-IV.
9. (Previously presented) A pharmaceutical composition comprising a selective denatured collagen type-IV antagonist according to Claim 2 and a pharmaceutically acceptable excipient.
10. (Original) The pharmaceutical composition of claim 9 wherein the composition comprises a cytotoxic agent.
11. (Original) The pharmaceutical composition of claim 9 wherein the composition comprises a radioactive material.
12. (Original) The pharmaceutical composition of claim 9 wherein the composition comprises a cytostatic agent.
- 13-37. (Canceled)